FDA approves multiple lisdexamfetamine dimesylate generics for ADHD in children

News
Article

Patients 6 years and up with ADHD now have alternate options for prescription lisdexamfetamine dimesylate (Vyvanse; Takeda Pharmaceuticals USA Inc), after the FDA-approval of multiple generic options.

FDA approves multiple lisdexamfetamine dimesylate generics for ADHD in children | Image Credit: © Stepan Popov- © Stepan Popov - stock.adobe.com.

FDA approves multiple lisdexamfetamine dimesylate generics for ADHD in children | Image Credit: © Stepan Popov- © Stepan Popov - stock.adobe.com.

The FDA has approved multiple first generics of lisdexamfetamine dimesylate (Vyvanse; Takeda Pharmaceuticals USA Inc) chewable tablets and capsules for patients 6 years and up with attention-deficit/hyperactivity disorder (ADHD), the federal agency announced in a press release on August 28, 2023.

Generic medicines approved by the FDA function in the same manner as the brand-name counterparts. A boxed warning informing health care providers about potential risk of dependence and abuse is listed for lisdexamfetamine dimesylate chewable tablets and capsules. Drugs containing amphetamines and methylphenidate, including lisdexamfetamine dimesylate, have a high potential for abuse, the FDA states. These drugs increase certain brain chemical levels, which can lead to addiction and overdose.

Warnings and precautions for serious cardiovascular reactions, blood pressure and heart rate increases, psychiatric adverse reactions, suppression of growth, peripheral vasculopathy, and serotonin syndrome (overage of serotonin that could be life-threatening) are also included in prescribing information for lisdexamfetamine dimesylate. See full prescribing information here.

According to the FDA, many abbreviated new drug applications (ANDAs) for lisdexamfetamine dimesylate received priority review. In children, adolescents, and adults with ADHD, the most common side effects for lisdexamfetamine dimesylate chewable tablets and capsules were anxiety, anorexia, decreased appetite, decreased weight, dry mouth, dizziness, insomnia, irritability, nausea, upper abdominal pain, and vomiting.

Patients with ADHD can have trouble with attention, controlling impulsive behaviors, and can be “overly” active, the FDA states. One of the most common neurodevelopmental disorders in childhood, ADHD affects approximately 10% of children. The disorder is typically diagnosed in childhood and can last into adulthood. It can be managed with “behavioral and pharmacological treatment, and some symptoms may improve as the child ages.”

In addition to approving these generics for children, adolescents and adults with ADHD, the generic chewable tablets and capsules are also approved for adults with moderate to severe binge-eating disorder (BED), as the most common side effects in this patient population were dry mouth, insomnia, decreased appetite, increased heart rate, feeling jittery, constipation, and anxiety.

Reference:

FDA approves multiple generics of ADHD and BED treatment. FDA. Press release. August 28, 2023. Accessed August 29, 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-multiple-generics-adhd-and-bed-treatment?utm_medium=email&utm_source=govdelivery

Recent Videos
Brittany Bruggeman, MD
Octavio Ramilo, MD
Lynn Malec, MD
DB-OTO improved hearing to normal in child with profound genetic deafness | Image Credit: © Marija - © Marija - stock.adobe.com.
Juanita Mora, MD
Rupa Wong, MD | Image Credit: Rupa Wong, MD
Tina Tan, MD, FAAP, FIDSA, FPIDS, editor in chief, Contemporary Pediatrics, professor of pediatrics, Feinberg School of Medicine, Northwestern University, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital of Chicago
John Bradley, MD
© 2024 MJH Life Sciences

All rights reserved.